Androgen deprivation therapy for prostate cancer

By Singer Eric A   Golijanin Dragan J   Miyamoto Hiroshi   Messing Edward M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 2, 2008-02 ,pp. : 211-228

Informa Healthcare

Access to resources Recommend Favorite

The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy

By  

Current Drug Targets, Vol. 14, Iss. 4, 2013-04 ,pp. : 420-440

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel plus estramustine and 15-month androgen deprivation therapy is feasible for the treatment of early prostate cancer relapse

By  

Inpharma, Vol. 1, Iss. 1568, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy

By  

Current Pharmaceutical Design, Vol. 12, Iss. 7, 2006-03 ,pp. : 785-798

Bentham Science Publishers

Access to resources Recommend Favorite

Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

By Taneja Samir S   Smith Matthew R   Dalton James T   Raghow Sharan   Barnette Gary   Steiner Mitchell   Veverka Karen A  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 293-305

Informa Healthcare

Access to resources Recommend Favorite